News | August 08, 2025
Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Subscribe To Our Newsletter & Stay Updated
